---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Conclusions"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Conclusions. 1 evidence topic quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary/conclusions"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

- Disease burden and unmet need: hereditary angioedema is estimated to affect 1 in 50,000 people worldwide, and a US claims-based algorithm estimated 9559, 9341, and 8694 people diagnosed in 2018, 2019, and 2020. Laryngeal involvement occurs at least once in about half of patients, and an analysis of studies including 3292 patients reported 411 deaths from asphyxia due to laryngeal edema. Except for oral sebetralstat, the approved on-demand treatments are given by intravenous or subcutaneous injection. In a survey of 107 respondents, sponsored by KalVista Pharmaceuticals, 57% did not treat all attacks and the mean time to treatment was 2.4 h; in a Pharvaris-supported survey, 84% of patients in the patient-reported group would prefer to take on-demand treatment by mouth.
- Regulatory status: the FDA accepted the New Drug Application for the deucrictibant immediate-release capsule (20 mg) for on-demand treatment of attacks in July 2026, and the European Medicines Agency validated the marketing authorization application in July 2026 and is reviewing it under the centralized procedure. The intended population is adults and adolescents 12 years and older. The company states that it has no drugs with regulatory approval and that FDA approval in 2027 is uncertain. A US expanded access program (NCT07759141) is open to eligible people aged 12 to 75 years.
- Efficacy of the 20 mg capsule: in RAPIDe-3, among 88 participants with one attack treated with each study drug, median time to onset of symptom relief was 1.28 h with deucrictibant and more than 12 h with placebo (p<0.0001), and median time to complete symptom resolution was 11.95 h and more than 48 h. Median time to end of progression was 17.47 min in the Lancet publication and 17.48 minutes in the NDA acceptance release. A single capsule was used within 12 h for 73 (83%) of 88 deucrictibant-treated attacks, and conventional on-demand rescue therapy within 12 h for six (7%) of 88 deucrictibant-treated and 32 (36%) of 88 placebo-treated attacks. In the phase 2 RAPIDe-1 trial, the least squares mean difference versus placebo in VAS-3 score change at 4 h was −15.02 for 20 mg. In Part A of the RAPIDe-2 extension, 19 participants blinded to doses of 10 mg, 20 mg, or 30 mg treated 465 attacks, with a median time to onset of symptom relief of 1.1 hours.
- Safety: in RAPIDe-3, treatment-emergent adverse events were reported by 24 (24%) of 100 participants receiving deucrictibant and 17 (17%) of 101 receiving placebo, and within 3 days by 15 (15%) and two (2%). Six treatment-related events in five deucrictibant-treated participants resolved within 24 h, and no treatment-emergent adverse events led to treatment discontinuation. An estimated 743 participants had been exposed to deucrictibant across 25 company-sponsored studies as of June 10, 2026, and no treatment-related cardiac or vascular disorder events occurred in the phase 1 single-dose studies, RAPIDe-1, RAPIDe-2 Part A, or RAPIDe-3.
- Main limitations of the RAPIDe-3 evidence: attacks were not stratified by location and severity, and severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Severe laryngeal attacks were not included, five adolescents were in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor. Eligibility required experience with effectively using conventional on-demand therapies and an age of 75 years or younger, and health-related quality of life outcomes were exploratory endpoints planned for separate publication.
- Relation to current on-demand options: guideline recommendations for first-line on-demand treatment include intravenous C1 inhibitor, icatibant, or sebetralstat, and one guideline states that sebetralstat is the only oral on-demand treatment available. Deucrictibant shares the bradykinin B2 receptor mechanism of icatibant, with a mean elimination half-life of approximately 5.1 h compared with approximately 1.5 h for icatibant. The company describes icatibant, available as a generic product, as the most widely used therapy, and a payer policy states that generic icatibant is the lowest cost of all available options. In the sebetralstat label, the median time to beginning of symptom relief was 2.0 hours with 600 mg, and 38% of patients administered a second dose within 12 hours; the RAPIDe-3 investigators state that variations in trial designs and instruments “prevent direct outcome comparisons”.
- Unknowns: no prescribing information, brand name, wholesale acquisition cost, or budget impact model for deucrictibant was identified; the company expects its product candidates, if approved, to be priced at a “significant premium over competitive generic products”. The company states that it has not conducted a head-to-head comparison of icatibant or any other drug candidate with deucrictibant. Long-term data come from the ongoing RAPIDe-2 study, whose Part A results combine three doses.
- Upcoming milestones: the PDUFA target action date is April 23, 2027, and the European Medicines Agency review is under way. The company expects revenue from sales of the immediate-release capsule in 2027 if the FDA approves it. RAPIDe-2 has an estimated primary completion of 2027-06, and the expanded access program is to continue for up to approximately 6 months after commercial availability.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/); [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf); [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf); [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf); [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf); [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf); [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/); [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2); [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application); [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm); [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [ClinicalTrials.gov NCT07759141](https://clinicaltrials.gov/study/NCT07759141); [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf); [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
